Stock Screener App

Gratuito -

Installare

43.53

1.00% -0.44

after-market

Dopo l'orario di chiusura: 43.53

Supernus Pharmaceuticals Inc (SUPN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché SUPN Giù? Forum Previsione

Supernus Pharmaceuticals Inc Borsa (SUPN) Ultime notizie

Indivior stock gains on raised 2026 guidance and Supernus deal - AD HOC NEWS

Supernus Pharmaceuticals Inc. (SUPN) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com

Supernus Pharmaceuticals to Participate in September Investor Conferences - Yahoo Finance

Chloe Kim will discuss her ADHD journey in Supernus partnership - Stock Titan

Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics - Barchart.com

Supernus Pharmaceuticals Inc. (SUPN) Peer Comparison – Compare with Others - Value Research

SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Super - The National Law Review

SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders - financialcontent.com

Is the Options Market Predicting a Spike in Supernus Pharmaceuticals Stock? - TradingView

A Look at Supernus Pharmaceuticals Inc (SUPN) After 3.4% Decline -- GF Value $43.78 vs Price $45.85 - GuruFocus

Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026 - Barchart.com

25,400 Shares in Supernus Pharmaceuticals, Inc. $SUPN Bought by Mystic Asset Management Inc. - MarketBeat

Indivior stock steadies after Supernus merger deal highlights $2.2 billion revenue goal - AD HOC NEWS

Supernus Pharmaceuticals (SUPN) Stock Looks Reasonable On Sales While Returns Look Strong - Sahm

Britannia, US WorldMeds, Supernus must face US Apokyn antitrust case, plaintiffs say - MLex

Supernus (SUPN) Results Review: The Available Earnings Metric Delivers a Beat in the Latest Reading; After Results: Shares Move 0.35% Lower in the Current UpdateGuidance Revision Trend - vinanet.vn

Supernus Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:SUPN) - TradingView

Indivior Q2 2026 Earnings Call: Complete Transcript - Sahm

Supernus Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript - Sahm

Rice Hall James & Associates LLC Takes $22.80 Million Position in Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat

Supernus Pharmaceuticals, Inc. $SUPN Shares Purchased by Bank of America Corp DE - MarketBeat

Details of Bhatt’s PSU Vesting and Tax Withholding at Supernus Pharmaceuticals - Kalkine Media

Supernus Pharmaceuticals CMO Jonathan Rubin Reports Vesting of 750 PSUs and Share Withholding for Taxes - Kalkine Media

Supernus Pharmaceuticals (SUPN) CEO exercises PSUs, withholds shares for taxes - Stock Titan

Supernus Pharmaceuticals (SUPN) CMO Rubin exercises PSUs and withholds shares for tax - Stock Titan

Supernus Pharmaceuticals (SUPN) SVP converts 1,650 PSUs; 797 shares withheld for taxes - Stock Titan

Supernus Pharmaceuticals (SUPN) exec converts 2,500 PSUs, withholds shares for tax - Stock Titan

Supernus Pharmaceuticals, Inc.: Revenue and Earnings Analysts Forecasts Revisions | SUPN | US8684591089 - marketscreener.com

Supernus Pharmaceuticals CEO Jack A. Khattar Completes Vesting of Performance Share Units - Kalkine Media

Morgan Lewis Advises Supernus Pharmaceuticals on Merger with Indivior Pharmaceuticals – News - Morgan Lewis

Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Assenagon Asset Management S.A. - MarketBeat

Why (SUPN) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Supernus Pharmaceuticals, Inc. (SUPN) Stock Forecasts - Yahoo Finance

Indivior Pharmaceuticals (INDV) Agrees Merger That Creates New Supernus, Inc. - simplywall.st

Supernus Pharmaceuticals, Inc. (SUPN) Investor Outlook: A 31% Upside Potential Amid Strong Revenue Growth - DirectorsTalk Interviews

Supernus Pharmaceuticals (SUPN) Stock May Be A Bargain After Merger News - Yahoo Finance

Supernus Pharmaceuticals Inc. (S49.SG) Q2 FY2025 earnings call transcript - Yahoo Finance

Supernus Pharmaceuticals (NASDAQ:SUPN) Rating Increased to Strong-Buy at Zacks Research - MarketBeat

supernus pharmaceuticals, inc. Positive Earnings Pre-Announcements - RTTNews

Arrowstreet Capital Limited Partnership Trims Holdings in Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat

Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to "Hold" at Wall Street Zen - MarketBeat

Supernus Pharmaceuticals, Inc. (SUPN) Indivior Pharmaceuticals, Inc.,M&A CallSlideshow - Seeking Alpha

Are BOW, ATKR, SUPN Obtaining Fair Deals for their Shareholders? - TradingView

Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc.SUPN - marketscreener.com

New Strong Buy Stocks for August 7th - The Globe and Mail

Best Value Stocks to Buy for August 7th - The Globe and Mail

Millennium group (SUPN) reports Supernus stake falls below 5% ownership - Stock Titan

Rockville-Based Supernus and Indivior Agree to Merge, Creating a $2.2B CNS Powerhouse Headquartered in Maryland - BioBuzz

Rx Rundown: Supernus Pharmaceuticals, TCGX, Sandoz and more - Medical Marketing and Media

Q2 2026 Supernus Pharmaceuticals Inc Earnings Call Transcript - GuruFocus

Supernus And Indivior To Merge And Create $2.2 Billion CNS Biopharmaceutical Company - Pulse 2.0

Supernus Pharmaceuticals Inc (SUPN) (Q2 2026) Earnings Call High - GuruFocus

Supernus Pharmaceuticals Inc (SUPN) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth ... - Yahoo! Finance Canada

Supernus Pharmaceuticals (NASDAQ:SUPN) Trading Down 6%Here's Why - MarketBeat

Supernus Pharmaceuticals Falls as Investors Weigh Newly Announced Indivior Merger Terms - moomoo.com

Supernus Pharmaceuticals falls as investors weigh newly announced Indivior merger terms - Quiver Quantitative

Supernus Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Supernus and Indivior to Merge, Creating Diversified CNS Biopharma Company - Contract Pharma

$1.8bn merger unites Supernus and Indivior in CNS therapeutics play - BioXconomy

INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook - Yahoo Finance

Supernus and Indivior merge to create scaled, CNS-focused entity - Yahoo Finance

Raleigh drug factory part of $2B merger - The Business Journals

Supernus Pharmaceuticals, Inc. (SUPN) Stock Analysis: Navigating A 38% Potential Upside - DirectorsTalk Interviews

Supernus Pharmaceuticals and Indivior Reveal All-Stock Merger of Equals Deal - Kalkine Media

ALKS

$46.10

1.66%

RDY

$11.97

0.50%

ELAN

$24.50

0.33%

NBIX

$155.64

1.71%

VTRS

$16.88

0.35%

UTHR

$487.61

0.54%

Apri su Yahoo | Apri su Google | Aperto in Finviz | Apri in MarketWatch | Aperto a EDGAR | Aperto su Reuters